7/28/2009

Giving patients with newly diagnosed Type 1 diabetes a low dose of recombinant human interferon-alpha may extend the "honeymoon phase" of the disease by preserving beta-cell function, according to a Phase II study of 128 patients, ages 3 to 25 years.

Related Summaries